These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 19740518

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
    Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L, Jass JR, Lugli A.
    Cancer; 2008 Feb 01; 112(3):495-502. PubMed ID: 18076013
    [Abstract] [Full Text] [Related]

  • 3. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer.
    Zlobec I, Minoo P, Baker K, Haegert D, Khetani K, Tornillo L, Terracciano L, Jass JR, Lugli A.
    Eur J Cancer; 2007 Apr 01; 43(6):1101-7. PubMed ID: 17350821
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC.
    Pancreas; 2008 Mar 01; 36(2):160-7. PubMed ID: 18376307
    [Abstract] [Full Text] [Related]

  • 5. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 01; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 6. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer.
    Zlobec I, Lugli A, Baker K, Roth S, Minoo P, Hayashi S, Terracciano L, Jass JR.
    J Pathol; 2007 Jul 01; 212(3):260-8. PubMed ID: 17516584
    [Abstract] [Full Text] [Related]

  • 7. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan 01; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K, Nozaki S, Kitahara H, Kato K, Noguchi N, Kawashiri S, Yamamoto E.
    Oncol Rep; 2011 Dec 01; 26(6):1555-60. PubMed ID: 21833477
    [Abstract] [Full Text] [Related]

  • 10. Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype.
    Paik SS, Jang KS, Song YS, Jang SH, Min KW, Han HX, Na W, Lee KH, Choi D, Jang SJ.
    Ann Surg Oncol; 2007 Dec 01; 14(12):3453-9. PubMed ID: 17882496
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 01; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 13. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
    Fujii T, Obara T, Tanno S, Ura H, Kohgo Y.
    Hepatogastroenterology; 1999 Aug 01; 46(28):2299-308. PubMed ID: 10521987
    [Abstract] [Full Text] [Related]

  • 14. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ, Duggan C.
    Clin Biochem; 2004 Jul 01; 37(7):541-8. PubMed ID: 15234235
    [Abstract] [Full Text] [Related]

  • 15. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A, Xue M, Jackson C, Smith RC.
    Int J Biochem Cell Biol; 2009 Jul 01; 41(8-9):1731-8. PubMed ID: 19433314
    [Abstract] [Full Text] [Related]

  • 16. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
    Chen WH, Wang C, Zhang YH, Yang YH, Zhan HY, Zhang LM.
    Zhonghua Yi Xue Za Zhi; 2007 Dec 04; 87(45):3228-32. PubMed ID: 18399120
    [Abstract] [Full Text] [Related]

  • 17. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer.
    Zlobec I, Terracciano L, Tornillo L, Günthert U, Vuong T, Jass JR, Lugli A.
    Gut; 2008 Oct 04; 57(10):1413-9. PubMed ID: 18436576
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
    Zhou H, Wu X, Lu X, Chen G, Ye X, Huang J.
    Thromb Res; 2009 Oct 04; 123(3):537-42. PubMed ID: 18691743
    [Abstract] [Full Text] [Related]

  • 19. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q, Liang LJ, Peng BG, Zhen YY.
    Ai Zheng; 2006 Nov 04; 25(11):1433-8. PubMed ID: 17094916
    [Abstract] [Full Text] [Related]

  • 20. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ.
    Oncol Rep; 2005 Jul 04; 14(1):235-9. PubMed ID: 15944795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.